Search Results - M. I. Kaleda

Ferritin is a complex protein composite (iron protein) that plays the role of the main intracellular iron depot in humans and animals, consisting of the protein apoferritin and the ferric atom in the composition of phosphate hydroxide. The reference value of ferritin in women is 200 μg/l, in men – 3...

Full description

Patients with juvenile-onset systemic lupus erythematosus (jSLE) account for up to 25% of all SLE patients. The main difference between jSLE and SLE in adults is the greater role of genetic factors in the pathogenesis, higher activity, earlier development of complications and the need for more aggre...

Full description

Systemic lupus erythematosus (SLE) is an autoimmune disease with various organs and systems involved in the pathological process, with an unpredictable course, a risk for life-threatening conditions, and an onset from childhood through adolescence in 10–20% of cases. The onset of SLE prior to adult...

Full description

According to current understanding of the mechanisms underlying primary immunodeficiencies (PIDs) and their clinical course, there is a clear and clinically significant association between this group of disorders and autoimmune manifestations (AIMs).This article presents up-to-date information on AI...

Full description

The introduction of tocilizumab — a drug that blocks interleukin 6 — into the practice of pediatric rheumatologists is an important achievement in the treatment of systemic juvenile arthritis (SJA). Objective: Our aim was to identify factors associated with the level of treatment response and safety...

Full description

Neuropsychiatric disorders in juvenile-onset systemic lupus erythematosus (SLE) stay in the focus of attention in recent decades due to significant influence of CNS lesions on SLE course in general, necessity to optimize therapeutic interventions and outline prognosis. This paper considers the preva...

Full description

Systemic juvenile arthritis (sJA) is one of the severest childhood somatic diseases. The relevance of the problem associated with sJA is determined by difficulties in early diagnosis, by the rapid development of disability, and by poor prognosis with a high risk for life-threatening conditions. It s...

Full description

The paper presents the results of a prospective trial of the efficiency and safety of tocilizumab (TCZ) therapy for sys- temic juvenile arthritis. It analyzes the impact of factors, such as age at onset of the disease, its duration at the time of TCZ therapy initiation,  the number of systemic manif...

Full description

The relevance of study systemic connective tissue diseases with juvenile onset for modern medicine is determined by the trend towards their growth in the population, the difficulty of early diagnosis, the rapid development of disability and a poor life prognosis. The article presents the main achiev...

Full description

The treatment of juvenile-onset systemic lupus erythematosus (jSLE) is a complex task in view of the diversity of clinical manifestations and the course of the disease as well as the high risk of organ damage. The need to create separate therapeutic principles for jSLE is justified by the greater in...

Full description

Systemic lupus erythematosus (SLE) with its onset in childhood or adolescence is a significant problem in the practice of pediatricians and rheumatologists due to diagnostic difficulties, clinical features, and the greater likelihood of unfavorable prognosis. About 20% of SLE patients fall ill at th...

Full description

Objective: to assess the frequency of prescription, efficacy and tolerability of biological disease-modifying antirheumatic drugs (bDMARDs) therapy in patients with major monogenic autoinflammatory diseases (mAID) according to the Federal Rheumatology Center clinical practice. Patients and methods....

Full description

The paper describes a patient with refractory systemic juvenile arthritis treated with tocilizumab (TCZ). Specific features of therapeutic response in real clinical practice, aspects of individual TCZ safety in the development of macrophage activation syndrome and concurrent therapy are discussed.

The paper describes a clinical case of severe systemic juvenile idiopathic arthritis (JIA) in a child with an early disease onset, which is resistant to multicomponent therapy (glucocorticoids, methotrexate, the tumor necrosis factor-α inhibitor etanercept), and the successful use of the anti-interl...

Full description

Numerous recent studies have shown that TNFAIP3 and TNF-α gene polymorphisms are associated with susceptibility to certain autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE), systemic scleroderma, rheumatoid arthritis, psoriasis, etc. However, the results of studies o...

Full description

Seropositive juvenile idiopathic arthritis (JIA) is one of the rarest and most unfavorable subtypes of juvenile arthritis, characterized by an increased frequency of inefficacy of therapy. Objective – to characterize biologic therapy in patients with seropositive JIA, to identify factors influencing...

Full description

The paper describes a clinical case of rheumatoid factor-seropositive polyarticular juvenile rheumatoid arthritis (JRA) concurrent with new-onset Sjo gren's syndrome (SS) in a teenage girl. It discusses the clinical features of SS and the problems of its diagnosis in pediatric practice. Erosive...

Full description

In juvenile onset systemic lupus erythematosus (SLE), musculoskeletal involvement is one of the most common manifestations. Musculoskeletal symptoms may be due to disease activity itself, organ damage due to SLE activity, drug exposure, or comorbidities. Although they are not life-threatening, they...

Full description

Objective: to assess the possibility of using varying interval between intravenous infusions of tocilizumab (TCZ) as a tool for choosing the optimal treatment regimen in systemic juvenile arthritis (SJA).Subjects and methods. The observational retrospective study included 72 patients (29 boys and 43...

Full description

In Russia, the interleukin-1 inhibitor canakinumab (fully human monoclonal antibodies to interleukin-1) is increasingly used for treating autoinflammatory diseases and systemic juvenile arthritis (sJIA). The article describes the experience of administering canakinumab in patients with autoinflammat...

Full description